Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDH1 | P40925 | 1/20 | 0.47 |
| ▸ | MDH2 | P40926 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 7/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22492924 | 0.91 | HRH3 (0.47) | MDH1MDH2MCHR1ALDH1A1GAA | |
| SCHEMBL19702889 | 0.90 | ALDH1A1 (0.52) | ALDH1A1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL19702876 | 0.89 | POLB (0.46) | ALDH1A1GAARAB9ASMN1; SMN2 | |
| SCHEMBL19702912 | 0.89 | OPRD1 (0.42) | MCHR1ALDH1A1GAAMAPTRAB9A | |
| SCHEMBL19702873 | 0.89 | TSHR (0.48) | MDH1MDH2ENPP2ALDH1A1GAA | |
| SCHEMBL19702884 | 0.88 | SMN1; SMN2 (0.51) | MCHR1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL19703084 | 0.88 | MDH1 (0.48) | MDH1MDH2ENPP2SLC6A5MCHR1 | |
| SCHEMBL19702293 | 0.88 | MDH1 (0.48) | MDH1MDH2ENPP2SLC6A5MCHR1 | |
| SCHEMBL19702878 | 0.88 | ALDH1A1 (0.48) | ALDH1A1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL19702886 | 0.86 | SMN1; SMN2 (0.42) | MCHR1ALDH1A1GAAMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200306248-A1 | FORMULATIONS FOR SUBSTITUTED 3-PYRROLIDINES, COMPOSITIONS CONTAINING, AND USES OF, SAME | GDD THERAPEUTICS, LLC (US) | 2020-10-01 | — | — | US | disclosed |
| WO-2017214201-A1 | FORMULATIONS FOR SUBSTITUTED 3-PYRROLIDINES, COMPOSITIONS CONTAINING, AND USES OF, SAME | THESAN PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306248-A1 | FORMULATIONS FOR SUBSTITUTED 3-PYRROLIDINES, COMPOSITIONS CONTAINING, AND USES OF, SAME | SLC7A1, ABCG2, SLC46A1 | MDH1 300/4885MDH2 577/4885ENPP2 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.